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Abstract
This study describes the antimicrobial resistance temporal trends and seasonal variation of
Escherichia coli (E. coli) urinary tract infections (UTIs) over five years, from 2009 to 2013,
and compares prevalence of resistance in hospital- and community-acquired E. coli UTI. A
cross sectional study of E. coli UTIs from patients attending a tertiary referral hospital in
Canberra, Australia was undertaken. Time series analysis was performed to illustrate resis-
tance trends. Only the first positive E. coli UTI per patient per year was included in the anal-
ysis. A total of 15,022 positive cultures from 8724 patients were identified. Results are
based on 5333 first E. coli UTIs, from 4732 patients, of which 84.2% were community-
acquired. Five-year hospital and community resistance rates were highest for ampicillin
(41.9%) and trimethoprim (20.7%). Resistance was lowest for meropenem (0.0%), nitrofur-
antoin (2.7%), piperacillin-tazobactam (2.9%) and ciprofloxacin (6.5%). Resistance to
amoxycillin-clavulanate, cefazolin, gentamicin and piperacillin-tazobactam were signifi-
cantly higher in hospital- compared to community-acquired UTIs (9.3% versus 6.2%;
15.4% versus 9.7%; 5.2% versus 3.7% and 5.2% versus 2.5%, respectively). Trend analy-
sis showed significant increases in resistance over five years for amoxycillin-clavulanate,
trimethoprim, ciprofloxacin, nitrofurantoin, trimethoprim-sulphamethoxazole, cefazolin, cef-
triaxone and gentamicin (P<0.05, for all) with seasonal pattern observed for trimethoprim
resistance (augmented Dickey-Fuller statistic = 4.136; P = 0.006). An association between
ciprofloxacin resistance, cefazolin resistance and ceftriaxone resistance with older age was
noted. Given the relatively high resistance rates for ampicillin and trimethoprim, these anti-
microbials should be reconsidered for empirical treatment of UTIs in this patient population.
Our findings have important implications for UTI treatment based on setting of acquisition.
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Introduction
Urinary tract infections (UTIs) are predominantly bacterial infections affecting people both in
the community and in hospitals [1]. Over 80% are caused by Escherichia coli (E. coli), a Gram
negative bacillus [2]. Data from the combined National Ambulatory Health Care Surveys in
the United States (US) for 2009–2010 showed that UTIs accounted for approximately 9.8 mil-
lion visits to ambulatory care settings such as primary care, outpatient and emergency depart-
ments [3]. Visits due to UTI were estimated to be 0.8% of all ambulatory care visits [3]. In
Australia, national data on UTI are unavailable but recent estimates from 82 hospitals and 17
aged care facilities reported a point prevalence of 1.4% and 1.5% respectively for healthcare
associatedUTIs [4].
While UTIs are a major infection burden globally, the growing problem of antimicrobial
resistance (AMR) can result in treatment failures and increased cost of healthcare [5]. There is
evidence to show that the AMR pattern of urinary E. coli is increasing [6]. In Switzerland, an
analysis of urinaryE. coli specimens obtained from a university hospital from 1997 to 2007
found an increasing trend in resistance to trimethoprim/sulfamethoxazole, ciprofloxacin and
amoxycillin/clavulanic acid (from 17.4% to 21.3%, 1.8% to 15.9%, and 9.5% to 14.5%, respec-
tively) [6]. The Australian Group on Antimicrobial Resistance (AGAR) which undertakes
AMR prevalence surveyswithin Australia also noted a gradual rise in overall percentage of E.
coli strains resistant to beta-lactam antibiotics and ciprofloxacin [7]. From 2009 to 2011, resis-
tance of hospital-onset E. coli isolates to ampicillin and ciprofloxacin increased from 48% to
51% and 8% to 11% respectively [7]. Furthermore, the resistance rates of urinaryE. coli to vari-
ous antimicrobials show large inter-country variability [8]. Only a few studies have shown that
E. coli resistance rates differ for hospital-acquired and community-acquired UTIs [9–11]. Mea-
suring and comparing the levels of AMR in both hospital- and community-acquired UTIs is
essential because although effects of AMR are mainly felt in healthcare facilities, the greatest
use of antimicrobials occurs in the community [12]. Comparing resistance rates in hospital-
and community-acquired UTIs may influence therapeutic recommendations for UTIs based
on setting of acquisition.
The prevalence of AMR including hospital and community urinaryE. coli resistance levels
is not completely known in Australia. Obtaining this information is important because it not
only provides knowledge about the health status of a population, but also contributes to disease
management decisions [13]. This study describes the AMR temporal trends and seasonal varia-
tion of E. coli UTI over five years at an Australian tertiary hospital. The study also compares
the prevalence of resistance between hospital- and community-acquired E. coli UTIs.
Materials and Methods
Study design and setting
A retrospective cross sectional design was used. The study was conducted with data from ACT
Pathology which is based at a tertiary referral hospital, the CanberraHospital and Health Ser-
vices. This is Australian Capital Territory’s (ACT) main hospital which provides acute and spe-
cialist care services to over 600,000 people in the surrounding region. The 600 bed publicly-
funded hospital which includes an emergency department and intensive care unit, offers a
comprehensive range of health services such as acute inpatient and day services, outpatient ser-
vices, women's and children's services and pathology services. Solid organ transplant services
are not offered in Canberra.
Human research ethics approval was granted by ACT Health Human Research Ethics Com-
mittee’s Low Risk Sub-Committee and Australian Catholic University Human Research Ethics
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Urine sample and data collection
The microbiology records of inpatients and those attending CanberraHospital who had urine
samples processed at ACT Pathology from January 2009 to December 2013 were retrospec-
tively reviewed.Demographic data and clinical information such as date of birth, gender,
admission date, specimen collection date and antimicrobial susceptibility test result were
obtained from the microbiology laboratory database and administrative record system.
Bacterial isolation and identification
Urine samples were analysed and processed based on the microbiology laboratory standards
[14]. For this study, a culture with presence of107 colony forming unit (cfu) per litre of urine
was considered positive for UTI based on the laboratory recommendations. This 107 cfu/L cut-
off is commonly used as it increases the sensitivity of the urine culture test making it a practical
threshold [15]. The criterion has also been used by several studies reporting on antimicrobial
resistance of urinaryE. coli [1,16,17]. Cultures with three or more bacterial species isolated
were considered contaminated and excluded. Only the first positive E. coli UTI per patient per
year was included in the final analysis.
Definitions
Urine cultures were classified based on the setting of acquisition of infection (hospital-acquired
and community-acquired, also known as hospital-onset and community-onset) using criteria
from the Centers for Disease Control and Prevention definitions [18]. Positive E. coli urine cul-
tures obtained within the first 48 hours of admission (including cultures from non-admissions
such as outpatient clinics) were defined as community-acquired UTIs. Positive cultures
obtainedmore than 48 hours after admission and within 48 hours of discharge were defined as
hospital-acquired UTIs.
Antimicrobial susceptibility testing
Antimicrobial susceptibility was performedby a disc diffusionmethod and the automated min-
imum inhibitory concentration (MIC) method using Vitek2 (BiomerieuxDiagnostics). Inter-
pretation was based on Clinical Laboratory Standard Institute (CLSI, formerly NCCLS) criteria
[19]. Based on a stepwise laboratory testing protocol used during the study period, all signifi-
cant E. coli (>107cfu/L) isolated after overnight incubation on culture had disc susceptibility
testing done. The antibiotic discs used for these tests were ampicillin (10μg), amoxycillin-clavu-
lanate (augmentin) (30μg), cephalexin/cefazolin (30 μg), trimethoprim (5μg), nalidixic acid
(30 μg), ciprofloxacin (5 μg), nitrofurantoin (300 μg) and gentamicin (10μg). The isolates
which were found to be resistant to at least three of the routinely tested antibiotics were then
sent for Vitek2 testing to determine the MICs for ceftriaxone, trimethoprim-sulphamethoxa-
zole, meropenem and piperacillin-tazobactamin addition to the routinely tested antibiotics.
Direct susceptibility testing method on urine specimens for E. coli has been validated at ACT
Pathology and is comparable to the CLSI recommendedmethods.
The quality control strains used for disc diffusion tests were E. coli ATCC 25922, E. faecalis
ATCC 29212 and for Vitek E. coli ATCC 25922, P. aeruginosa ATCC 27853, E. faecalis ATCC
29212, S. aureus ATCC 29213.
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Extended spectrum beta lactamase (ESBL) confirmation
Detection of ESBL-producing isolates was performedwith combination discs of cefotaxime
(30μg), cefotaxime/clavulanic acid (30/10μg), ceftazidime (30μg) and ceftazidime/clavulanic
acid (30/10μg) whenever required according to CLSI guidelines [15]. Extended spectrumbeta
lactamase production was inferred when the zone diameter of the disc with clavulanate was
5mm larger than the disc without clavulanate for the same antibiotic. K. pneumoniae ATCC
700603 was used as the quality control strain.
Statistical analysis
The overall 5-year and yearly resistance rates of E. coli to the routinely tested first-line antimi-
crobials on over 4,000 isolates (ampicillin, amoxycillin-clavulanate, cephalexin/cefazolin, cipro-
floxacin, gentamicin, nalidixic acid, and trimethoprim)were calculated by dividing the number
of urinaryE. coli isolates resistant to each antimicrobial by the number of isolates tested against
an individual antimicrobial agent. For the isolates which were sent for further susceptibility test-
ing on Vitek2 against second-line antimicrobials (ceftriaxone, trimethoprim-sulphamethoxa-
zole, meropenem, piperacillin-tazobactamand nitrofurantoin), the denominator used in
calculating the resistance rates was the total number of isolates included in the study. This
denominator was used based on the assumption that isolates were initially not tested for the
Vitek2 antibiotics because they were considered highly unlikely to be resistant to these antibiot-
ics. Hence in order not to overestimate the resistance rates of these isolates the denominator
included all isolates tested on both antibiotic discs and Vitek2. The binomial exact 95% confi-
dence intervals (CI) of the resistance percentages were calculated. The 5-year resistance rates
were compared for community- and hospital-acquired isolates. The chi-square test was used to
check for statistically significant differences in AMR between both groups. Mean differences in
age between the two groups were tested using Student’s t-tests. A time series analysis was per-
formed separately for all antimicrobials tested to identify patterns in resistance (trends and sea-
sonal variation) over the five year period. Seasonality is a pattern that shows periodic repetitive
fluctuations over time. An autoregressive (AR) model was constructed to assess time-varying
resistance patterns (i.e., resistance is non-stationary, or changing, over time) and multiple time
seriesmodels were fitted to also account for age and sex. The analysis on age and sex followed
an ecological study design because these variables were aggregated for each season. The Dickey-
Fuller (DF) and the augmented Dickey-Fuller (ADF) tests were used to assess a unit root in the
time series data. Both DF and ADF statistics are negative numbers; the more negative, the stron-
ger the rejection of the null hypothesis (that there is unit root at some level of confidence).
These unit root tests investigate whether a time series variable (e.g., resistance) is non-stationary
using the ARmodel [20]. Urinary E. coli isolates for which the antimicrobial showed an inter-
mediate susceptibility category (amoxycillin-clavulanate, trimethoprim, and ciprofloxacin) were
excluded from the final analysis. A significance level of P< 0.05 was used. Data were analysed
using STATA statistical software (version 13, StataCorp).
Results
A total of 106,512 urine samples from 47,727 patients attending CanberraHospital from 2009
to 2013 were processed by ACT Pathology. Of these, 14.1% (n = 15,022) had positive cultures
with E. coli being the most common organism isolated in 7670 (51.1%) samples. The distribu-
tion of samples by study year is shown in S1 Table.
Of the 7670 E. coli cultures, most (7103 isolates) could be further classified as community-
or hospital-acquired UTI based on available data. The data were then restricted to the first pos-
itive E. coli UTI per patient per year of which there were 5346 positive E. coli UTIs but only
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5333 had susceptibility test results. Hence 5333 E. coli UTIs belonging to 4732 patients in the
5-year periodwere included in the final analysis. The majority (84.2%, n = 4492) of UTIs were
classified as community-acquired and 15.8% (n = 841) as hospital-acquired. The mean age of
all patients was 57.0 years (SD = 27.5) and patients were mostly female (80.2%, n = 3795).
There was a significant difference in age between patients with hospital- and community-
acquired E. coli UTI (mean age 67.2 years versus 55.1 years, P<0.001) but no significant differ-
ences in gender.
Antimicrobial resistance
All 5333 isolates had routine susceptibility testing performed against first-line antimicrobials
and the overall 5-year and stratified (hospital- and community-acquired) AMR rates are sum-
marised in Table 1. Of the 5333 isolates, 1599 (29.9%) were sent for further antimicrobial sus-
ceptibility testing for second-line antimicrobials on Vitek2. The overall 5-year resistance rates
to these second-line antimicrobials are reported in Table 2.
The highest overall 5-year resistance rates to urinaryE. coli for both hospital and commu-
nity isolates combined were seen for ampicillin (41.9%; 95% CI = 40.6–43.3) and trimethoprim
(20.7%; 95% CI = 19.6–21.8). The lowest resistance rates were for meropenem (0.0%), nitrofur-
antoin (2.7%; 95% CI = 2.3–3.2) and piperacillin-tazobactam(2.9%; 95% CI = 2.5–3.4). Resis-
tance to amoxycillin-clavulanate, cephalexin/cefazolin, gentamicin and piperacillin-
tazobactamwas significantly higher in hospital- compared to community-acquired UTIs
(P<0.001, P<0.001, P = 0.043 and P = 0.002, respectively). For ampicillin, trimethoprim, nali-
dixic acid, ciprofloxacin, ceftriaxone and trimethoprim-sulphamethoxazole, resistance rates
were also higher for hospital- compared with community-acquired UTI but this did not reach
statistical significance (Fig 1).
Trend analysis showed a significant increase in resistance to amoxycillin-clavulanate, tri-
methoprim, ciprofloxacin, nitrofurantoin, trimethoprim-sulphamethoxazole, cefazolin, ceftri-
axone and gentamicin over the five year period (Fig 2). There was no significant increase in
resistance for ampicillin, nalidixic acid, meropenem and piperacillin-tazobactam.A seasonal
pattern was only observed for trimethoprim (ADF statistic = -4.136; P = 0.006) with higher
resistance rates for this antimicrobial seen in the summer months. Regression analysis indi-
cated an association between increasing age and resistance to ciprofloxacin (regression coeffi-
cient = 0.01; P = 0.004), cefazolin (regression coefficient= 0.004; P = 0.038) and ceftriaxone
(regression coefficient= 0.01; P = 0.002).
ESBL production
Overall 5-year prevalence of ESBL-producing E. coli isolates was 1.9% (95% CI = 1.5–2.3;
n = 100). Extended spectrumbeta-lactamase production was low by international standards
but was significantly higher in hospital-acquired (3.0%; 95% CI = 1.9–4.4; n = 25) compared
with community-acquired UTIs (1.7%; 95% CI = 1.3–2.1; n = 75, P = 0.01). The levels of ESBL-
producing E. coli increased from 0.7% (95% CI = 0.0–3.8) in hospital-acquired UTIs in 2009 to
6.5% (95% CI = 3.2–11.6) in 2013. An increase was also noted for community-acquired UTIs
(0.6%; 95% CI = 0.2–1.4 in 2009 to 3.7%; 95% CI = 2.5–5.3 in 2013). The increasing trend in
ESBL production over the five years was statistically significant for both hospital (P = 0.035)
and community-acquired UTIs (P<0.001).
Discussion
This study provides information about the AMR pattern of E. coli UTIs in an Australian ter-
tiary hospital. To our knowledge this is the first Australian study to compare AMR in
Time Series Analysis of Antimicrobial Resistant E. coli
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Table 1. Resistance profile of urinary E. coli isolates sent for routine susceptibility testing from 2009 to 2013 by setting.
COMMUNITY HOSPITAL TOTAL
Antibiotic Year Number of
community
isolates tested
R n (%) 95% CI of
resistance
percentage
Number of
hospital
isolates
tested
R n (%) 95% CI of
resistance
percentage
Total
number of
isolates
tested*
R n (%) 95% CI of
resistance
percentage
Ampicillin 2009 835 331 (39.6) 36.3–43.1 143 71 (49.7) 41.2–58.1 978 402 (41.1) 38.0–44.3
2010 897 358 (39.9) 36.7–43.2 182 70 (38.5) 31.4–45.9 1079 428 (39.7) 36.7–42.7
2011 1037 443 (42.7) 39.7–45.8 189 91 (48.2) 40.8–55.5 1226 534 (43.6) 40.8–46.4
2012 939 412 (43.9) 40.7–47.1 173 74 (42.8) 35.3–50.5 1112 486 (43.7) 40.8–46.7
2013 784 315 (40.2) 36.7–43.7 154 71 (46.1) 38.1–54.3 938 386 (41.2) 38.0–44.4
Total 4492 1859
(41.4)
39.9–42.8 841 377
(44.8)
41.4–48.3 5333 2236
(41.9)
40.6–43.3
AMC 2009 785 24 (3.1) 2.0–4.5 133 6 (4.5) 1.7–9.6 918 30 (3.3) 2.2–4.6
2010 832 49 (5.9) 4.4–7.7 172 11 (6.4) 3.2–11.2 1004 60 (6.0) 4.6–7.6
2011 981 61 (6.2) 4.8–7.9 170 17 (10.0) 5.9–15.5 1151 78 (6.8) 5.4–8.4
2012 895 71 (7.9) 6.2–9.8 161 19 (11.8) 7.3–17.8 1055 89 (8.4) 6.8–10.3
2013 754 58 (7.7) 5.9–9.8 145 23 (15.9) 10.3–22.8 899 81 (9.0) 7.2–11.1
Total 4247 263 (6.2) 5.5–6.9 781 76 (9.3) 7.7–12.0 5027 338 (6.7) 6.0–7.5
Cefazolin 2009 821 60 (7.3) 5.6–9.3 129 14 (10.9) 6.1–17.5 950 74 (7.8) 6.2–9.7
2010 885 96 (10.9) 8.9–13.1 179 24 (13.4) 8.8–19.3 1064 120 (11.3) 9.4–13.3
2011 1019 103 (10.1) 8.3–12.1 178 30 (16.9) 11.7–23.2 1197 133 (11.1) 9.4–13.0
2012 917 82 (8.9) 7.2–11.0 168 26 (15.5) 10.4–21.8 1085 108 (10.0) 8.2–11.9
2013 776 89 (11.5) 9.3–13.9 151 30 (19.9) 13.8–27.1 927 119 (12.8) 10.8–15.2
Total 4418 430 (9.7) 8.9–10.6 805 124
(15.4)
13.0–18.1 5223 554 (10.6) 9.8–11.5
Trimethoprim 2009 830 153 (18.4) 15.9–21.2 143 28 (19.6) 13.4–27.0 973 181 (18.6) 16.2–21.2
2010 897 172 (19.2) 16.6–21.9 181 33 (18.2) 12.9–24.6 1078 205 (19.0) 16.7–21.5
2011 1036 217 (20.9) 18.5–23.6 189 42 (22.2) 16.5–28.8 1225 259 (21.1) 18.9–23.5
2012 939 200 (21.3) 18.7–24.1 173 40 (23.1) 17.1–30.1 1112 240 (21.6) 19.2–24.1
2013 784 181 (23.1) 20.2–26.2 154 36 (23.4) 16.9–30.9 938 217 (23.1) 20.5–26.0
Total 4486 923 (20.6) 19.4–21.8 840 179
(21.3)
18.6–24.2 5326 1102
(20.7)
19.6–21.8
Nalidixic acid 2009 826 63 (7.6) 5.9–9.7 143 12 (8.4) 4.4–14.2 969 75 (7.7) 6.1–9.6
2010 892 73 (8.2) 6.5–10.2 182 12 (6.6) 3.5–11.2 1074 85 (7.9) 6.4–9.7
2011 1034 109 (10.5) 8.7–12.6 188 22 (11.7) 7.5–17.2 1222 131 (10.7) 9.0–12.6
2012 755 56 (7.4) 5.7–9.5 140 17 (12.1) 7.2–18.7 895 73 (8.2) 6.4–10.1
2013 585 33 (5.6) 3.9–7.8 103 11 (10.7) 5.5–18.3 688 44 (6.4) 4.7–8.5
Total 4092 334 (8.2) 7.3–9.0 756 74 (9.8) 7.8–12.1 4848 408 (8.4) 7.6–9.2
Ciprofloxacin 2009 808 33 (4.1) 2.8–5.7 139 7 (5.0) 2.0–10.1 947 40 (4.2) 3.0–5.7
2010 701 35 (5.0) 3.5–6.9 150 4 (2.7) 0.7–6.7 851 39 (4.6) 3.3–6.2
2011 795 52 (6.5) 4.9–8.5 156 10 (6.4) 3.1–11.5 951 62 (6.5) 5.0–8.3
2012 749 56 (7.5) 5.7–9.6 143 11 (7.7) 3.9–13.3 892 67 (7.5) 5.9–9.4
2013 631 60 (9.5) 7.3–12.1 135 17 (12.6) 7.5–19.4 766 77 (10.1) 8.0–12.4
Total 3684 236 (6.4) 5.6–7.2 723 49 (6.8) 5.1–8.9 4407 285 (6.5) 5.8–7.2
Gentamicin 2009 514 17 (3.3) 1.9–5.2 85 5 (5.9) 1.9–13.2 599 22 (3.7) 2.3–5.5
2010 893 23 (2.6) 1.6–3.8 182 2 (1.1) 0.1–3.9 1075 25 (2.3) 1.5–3.4
2011 1036 38 (3.7) 2.6–5.0 189 12 (6.4) 3.3–10.8 1225 50 (4.1) 3.0–5.3
2012 931 40 (4.3) 3.1–5.8 172 12 (7.0) 3.7–11.9 1102 52 (4.7) 3.5–6.1
2013 783 36 (4.6) 3.2–6.3 154 10 (6.5) 3.2–11.6 937 46 (4.9) 3.6–6.5
(Continued )
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hospital- and community-acquired E. coli UTI and assess AMR temporal trends and seasonal
variation of E. coli UTI over time. Our results showed that overall resistance was highest for
ampicillin and trimethoprim.We also found significantly higher resistance rates in hospital-
compared to community-acquired UTIs for amoxycillin-clavulanate, cephalexin/cefazolin,
gentamicin and piperacillin-tazobactamwith an increasing resistance trend for eight of the
twelve antimicrobials tested which include the four commonly used antimicrobials for first
line treatment of UTI in Australia.
In Australia, trimethoprim, cephalexin, amoxycillin-clavulanate or nitrofurantoin are recom-
mended for first line treatment of UTI [21]. The Infectious Diseases Society of America (IDSA)
and European Society for Microbiology and Infectious Diseases recommend trimethoprim-sul-
phamethoxazole as an appropriate treatment choice if local resistance rates do not exceed 20%.
The IDSA guidelines also recommend that amoxycillin or ampicillin should not be used alone
for empirical treatment because of the relatively poor efficacy and the relatively high prevalence
of AMR to these agents worldwide [22]. Given the high levels of resistance to ampicillin and tri-
methoprim identified in this study, the appropriateness of these antimicrobials in the manage-
ment of UTI in this patient population should be assessed. The IDSA suggests that beta-lactam
agents, including amoxycillin-clavulanate are appropriate choices for therapy when other rec-
ommended agents cannot be used [22]. Based on our findings, the majority of UTIs have very
low resistance to amoxycillin-clavulanate and nitrofurantoin which are commonly used for UTI
treatment in Canberra. Ciprofloxacin, which is recommended in Australia for complicated
UTIs, was also found to have a low resistance rate. Through the national pharmaceutical subsidy
scheme, the use of quinolones in humans has been restricted in Australia. Quinolone use in
food-producing animals is also not permitted. Therefore, fluoroquinolone resistance in the com-
munity has been slow to emerge and has remained at low levels in important pathogens such as
E. coli compared to most countries [23]. Our overall resistance rates are also generally lower
than reported for other single site studies [9,24], demonstrating that resistance may vary geo-
graphically, as shown in a recent meta-analysis [25]. The explanation for the varying resistance
rates is not clearly understood but possible reasons have been postulated. A study conducted in
the United States demonstrated a geographic gradient in resistance with the highest resistance
rates noted in the Pacific region and lowest rates in the South Atlantic region [26]. It was sug-
gested that geographic clustering of resistance phenotypes may have accounted for the geo-
graphic differences in resistance. It is therefore possible that the lower rates we found in
comparison to those reported for other single site studies may be due to lower levels of bacteria
with resistance phenotypes in our locality. Another possible suggestion for geographic variation
Table 1. (Continued)
COMMUNITY HOSPITAL TOTAL
Antibiotic Year Number of
community
isolates tested
R n (%) 95% CI of
resistance
percentage
Number of
hospital
isolates
tested
R n (%) 95% CI of
resistance
percentage
Total
number of
isolates
tested*
R n (%) 95% CI of
resistance
percentage
Total 4157 154 (3.7) 3.2–4.3 782 41 (5.2) 3.8–7.0 4938 195 (3.9) 3.4–4.5
*Note that not all 5333 isolates were tested against each antimicrobial. Isolates not tested: AMC = 3; Cephazolin = 110; Trimethoprim = 3; Nalidixic
acid = 485; Ciprofloxacin = 893; Gentamicin = 395
Number of isolates with intermediate susceptibility to an antimicrobial: AMC = 303; Trimethoprim = 4; Ciprofloxacin = 33
R = Resistant
n = Number of isolates
AMC = Amoxycillin-clavulanate; TMP-SMX = Trimethoprim-sulphamethoxazole
doi:10.1371/journal.pone.0164306.t001
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in resistance is the differences in antimicrobial use [26,27]. Several studies have demonstrated
an association between antimicrobial use and resistance [28–30]. Hence it is probable that the
lower resistance noted may be as a result of lower antimicrobial use resulting in lower antimi-
crobial selection pressure. This emphasizes the need for continuous local monitoring of resis-
tance patterns to ensure appropriate treatment for people in the locality.
The sample size of the data was able to detect some significant differences between com-
munity- and hospital-acquired UTI resistance rates but for some antimicrobials the differ-
ences observed could not be confirmed statistically, possibly due to an insufficient sample
size. Overall, we found lower rates of antibiotic resistance for community- compared with
Table 2. Resistance profile of urinary E. coli isolates sent for further testing on Vitek2 from 2009 to 2013 by setting.
Year Setting N Antibiotic
Ceftriaxone TMP-SMX MER PIT NIT
R n (%) 95% CI of
resistance
percentage
R n (%) 95% CI of
resistance
percentage
R n
(%)
95% CI of
resistance
percentage
R n
(%)
95% CI of
resistance
percentage
R n (%) 95% CI of
resistance
percentage
2009 CA 835 12 (1.4) 0.7–2.5 58 (6.9) 5.3–8.9 0 (0.0) - 2 (0.2) 0.0–0.9 14 (1.7) 0.9–2.8
HA 143 2 (1.4) 0.2–5.0 12 (8.4) 4.4–14.2 0 (0.0) - 0 (0.0) - 4 (2.8) 0.8–7.0
Total 978 14 (1.4) 0.8–2.4 70 (7.2) 5.6–9.0 0 (0.0) - 2 (0.2) 0.0–0.7 18 (1.8) 1.1–2.9
2010 CA 897 22 (2.5) 1.5–3.7 76 (8.5) 6.7–10.5 0 (0.0) - 27
(3.0)
2.0–4.3 15 (1.7) 0.9–2.7
HA 182 4 (2.2) 0.6–5.5 11 (6.0) 3.1–10.6 0 (0.0) - 4 (2.2) 0.6–5.5 5 (2.7) 0.9–6.3
Total 1079 26 (2.4) 1.6–3.5 87 (8.1) 6.5–9.9 0 (0.0) - 31
(2.9)
2.0–4.1 20 (1.9) 1.1–2.8
2011 CA 1037 46 (4.4) 3.3–5.9 99 (9.5) 7.8–11.5 0 (0.0) - 19
(1.8)
1.1–2.8 17 (1.6) 1.0–2.6
HA 189 13 (6.9) 3.7–11.5 30 (15.9) 11.0–21.9 0 (0.0) - 9 (4.8) 2.2–8.8 3 (1.6) 0.3–4.6
Total 1226 59 (4.8) 3.7–6.2 129 (10.5) 8.9–12.4 0 (0.0) - 28
(2.3)
1.5–3.3 20 (1.6) 1.0–2.5
2012 CA 939 43 (4.6) 3.3–6.1 102 (10.9) 8.9–13.0 1 (0.1) 0.0–0.6 33
(3.5)
2.4–4.9 35 (3.7) 2.6–5.1
HA 173 13 (7.5) 4.1–12.5 22 (12.7) 8.1–18.6 0 (0.0) - 15
(8.7)
4.9–13.9 5 (2.9) 0.9–6.6
Total 1112 56 (5.0) 3.8–6.5 124 (11.1) 9.4–13.1 1 (0.1) 0.0–0.5 48
(4.3)
3.2–5.7 40 (3.6) 2.6–4.9
2013 CA 784 45 (5.7) 4.2–7.6 87 (11.1) 9.0–13.5 0 (0.0) - 30
(3.8)
2.6–5.4 42 (5.4) 3.9–7.2
HA 154 15 (9.7) 5.6–15.6 25 (16.2) 10.8–23.0 0 (0.0) - 16
(10.4)
6.1–16.3 4 (2.6) 0.7–6.5
Total 938 60 (6.4) 4.9–8.2 112 (11.9) 9.9–14.2 0 (0.0) - 46
(4.9)
3.6–6.5 46 (4.9) 3.6–6.5
Total CA 4492 168
(3.7)
3.2–4.3 422 (9.4) 8.6–10.3 1 (0.0) 0.0–0.1 111
(2.5)
2.0–3.0 123
(2.7)
2.3–3.3
HA 841 47 (5.6) 4.1–7.4 100 (11.9) 9.8–14.3 0 (0.0) - 44
(5.2)
3.8–7.0 21 (2.5) 1.6–3.8
Total 5333 215
(4.0)
3.5–4.6 522 (9.8) 9.0–10.6 1 (0.0) 0.0–0.1 155
(2.9)
2.5–3.4 144
(2.7)
2.3–3.2
R = Resistant
N = Number of isolates tested
CA = Community isolates; HA = Hospital isolates
TMP-SMX = Trimethoprim-sulphamethoxazole; MER = Meropenem; PIT = Piperacillin-tazobactam; NIT = Nitrofurantoin
doi:10.1371/journal.pone.0164306.t002
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hospital-acquired E. coli UTIs, consistent with other studies [9,31]. The difference in resis-
tance rates is however only small and supports the view that E. coli, a bacterium carried in
the bowel and acquired in the community, is brought into hospital usually by patients them-
selves rather than being hospital-acquired. This findingmay also have been partially dictated
by our methodology from using the first positive UTI per person per year. The different
resistance rates for hospital- and community-acquired urinary E. coli isolates seen in this
study are comparable with findings reported previously [10,11]. Similar results have been
seen in blood culture isolates of E. coli in Canberra [32]. While the difference in resistance
rates was not large and most antimicrobial use occurs in the community, the proportion of
patients receiving antimicrobials is much higher in the hospital and hence explains the dif-
ference seen [33]. We agree with recommendations that to accurately represent E. coli resis-
tance rates, antibiograms should be stratified by setting of infection onset [34].
The increasing resistance trend noted in our study for the eight antimicrobials is consistent
with previously reported Australian data and published studies from other developed countries
[6,7,9,35,36]. The increasing trend may be attributable to antimicrobial overuse or misuse
which is a known risk factor for the development of AMR [37]. However, clinical data on hos-
pital antimicrobial use at the study location showed stable rates for most antimicrobials tested
(data not shown). We also found seasonal increases in trimethoprim resistance especially in
summer months. The literature suggests a possible seasonality with UTI incidence [38,39] but
this was not demonstrated in our study. It is possible that seasonality in UTI may lead to sea-
sonal variation in antimicrobial use with subsequent seasonal resistance patterns although to
Fig 1. Five-year resistance rates of hospital- and community-acquired E. coli UTIs by selected antibiotics.
amp = ampicillin; tri = trimethoprim; cef = cefazolin; amc = amoxycillin-clavulanate; cip = ciprofloxacin; pit = piperacillin-
tazobactam; gen = gentamicin; nit = nitrofurantoin. ** 0.001 < p value < 0.05. ** p < 0.001
doi:10.1371/journal.pone.0164306.g001
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our knowledge, this is yet to be demonstrated in published studies. Evidence currently exists to
show higher use of antimicrobials in winter months which is likely related to the increased inci-
dence of respiratory tract infections during that periodwith consequent increases in resistance
during winter [40,41]. Therefore the seasonal trimethoprim resistance is a potentially impor-
tant finding which should be explored in future studies especially in relation to antimicrobial
use. The ecological analysis conducted in this study showed an association between older age
and resistance to ciprofloxacin, cefazolin and ceftriaxone consistent with published studies
[6,34,42]. The association between increasing age and increased resistance is not surprising
given that the physiological changes caused by aging and increased comorbidities predispose to
a higher risk of infection leading to more contact with healthcare settings and hence more fre-
quent exposure to antibiotics [42].
It is worth emphasizing that our overall ESBL rate of 1.9% was low compared to most other
published studies [31]. Results from the 2009–2011 SMART study in the United States
reported an ESBL rate of 6.8% for E. coli UTI [31]. Although our reported ESBL rate is rela-
tively low, the presence and increasing trend of ESBL-producing E. coli in both hospital and
community-acquired UTIs pose considerable public health concern. This is because this organ-
ism renders many of the conventional empirical treatment options for UTI ineffective espe-
cially in community-acquired UTI where options for oral antibiotic therapy appear to be
limited [43]. For hospital-acquired UTI caused by ESBL-producing E. coli, carbapenems are
considered the treatment of choice [43]. In our study, the lowest resistance rate reported was
for meropenem, a carbapenem.
This study has some limitations. As most UTIs are treated empirically, it is possible that sam-
ples submitted to the laboratory included patients with recurrent UTIs and asymptomatic
Fig 2. Seasonal antimicrobial resistance rates for E. coli UTIs. 1 = Summer; 2 = Autumn; 3 = Winter;
4 = Spring. P = significance level for an increasing trend. AMC = Amoxycillin-clavulanate;
TMP-SMX = Trimethoprim-sulphamethoxazole
doi:10.1371/journal.pone.0164306.g002
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bacteriuria thereby overestimating the resistance rates. In addition, inclusion of the first positive
E. coli UTI per person per year may have underestimated the resistance rates reported in our
study. Evidence suggests that analysis of antimicrobial resistance data should include each indi-
vidual positive isolate in order to ensure sensitivity, but this positive isolate should only be
included once to guarantee specificity [44]. This approach of using only the first positive isolate
per patient per year is also consistent with published studies on resistance in UTI pathogens
including E. coli [17,34]. It is unlikely that repeated isolates are correlated but there is a small
possibility that this could occur although it was not accounted for in the analysis. The 5-year
period prevalence study could therefore have overestimated the resistance. The use of routinely
collectedmicrobiology data also posed some limitations as clinical information on patients
including comorbidities and presence of indwelling urethral catheters was often missing. The
incompleteness of this information prevented its inclusion in the analysis. This study was based
on retrospective antimicrobial susceptibility data from a National Association of Testing
Authorities, Australia (NATA) accredited clinical microbiology laboratory. The stepwise labora-
tory testing protocol involved routine first-line antibiotic sensitivity testing followed by more
extensive testing with second-line antibiotics only for isolates resistant to at least three of the
routine antibiotics. Although this laboratory approach is widely used [44] there is the potential
for testing bias and/or selection bias with consequent overestimation of resistance rates. Given
the lack of consensus on an appropriate denominator using this testing approach and to prevent
possible overestimation of the resistance rates against second-line antibiotics, the denominator
therefore included all isolates tested, which, in turn, may have under-estimated resistance rates
of broad spectrumantimicrobials. Determining the resistance rate can be influenced by the
extent of laboratory testing which in turn influences the selection of the denominator. Using the
total number of isolates tested or the number of isolates tested against second-line antibiotics
alone as the denominator will either underestimate or overestimate the resistance rates respec-
tively. Although using all isolates for calculating resistance rates for second-line antibiotics has
its limitations, this was an appropriate denominator choice to make the findings relevant for use
in the clinical setting. For ideal comparison of susceptibility patterns, all isolates would need to
be tested against the extended panel of antibiotics in a properly designed prospective study.
Regardless of these limitations, our reported resistance rates are low compared to other studies.
The use of ecological data to account for the effects of age and sex on resistance also poses limi-
tations to interpretation of these results at the individual patient level. Although our data are
from a single tertiary hospital and may not be generalisable to other populations, the data were
reported by a NATA accredited laboratory and are therefore satisfactory to provide recommen-
dations to guide local empirical therapy.
Conclusions
Antimicrobial resistance poses grave concerns for antimicrobial effectiveness in treating infec-
tions such as UTI. This study demonstrates the increasing resistance of urinaryE. coli to com-
monly prescribed antimicrobials. Amoxycillin-clavulanate and nitrofurantoin are still effective
for empirical treatment of UTI in this population. Overuse of ampicillin and trimethoprim
should be avoided given the high resistance rates reported. In developing local antimicrobial
prescribing guidelines, the choice of antimicrobial in the treatment of UTI should be based on
setting (community or hospital) of acquisition.
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